Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.28 EUR
Change Today -0.004 / -1.41%
Volume 1.8M
PHARM On Other Exchanges
EN Amsterdam
As of 11:35 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

pharming group nv (PHARM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/17/14 - €0.65
52 Week Low
07/7/15 - €0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMING GROUP NV (PHARM)

Related News

No related news articles were found.

pharming group nv (PHARM) Related Businessweek News

No Related Businessweek News Found

pharming group nv (PHARM) Details

Pharming Group N.V. develops, produces, and commercializes human therapeutic proteins for unmet medical needs. It is involved in the production, purification, formulation, and development of recombinant protein products. The company offers Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor (rhC1INH) for ischemia-reperfusion injury (IRI) indications, including myocardial infarction, stroke, and delayed graft function in transplantation; and rhFactor VIII for Haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

53.8 Employees
Last Reported Date: 03/18/15

pharming group nv (PHARM) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €624.0K
Chief Operations Officer and Member of Manage...
Total Annual Compensation: €391.0K
Compensation as of Fiscal Year 2014.

pharming group nv (PHARM) Key Developments

Pharming Group NV Announces Interim Results from the Ongoing Phase II Pediatric Clinical Trial of RUCONEST

Pharming Group NV announced the presentation of new results, supporting its EMA and FDA approved Hereditary Angioedema (HAE) therapy RUCONEST®, at the 9thC1- Inhibitor Deficiency Workshop that took place in Budapest, Hungary, 28-31 May 2015. Several abstracts, including two oral presentations, were presented, which demonstrate Pharming's ongoing commitment to advance innovative science in HAE, with the goal of addressing significant clinical needs and improving patient care. The presentations featured interim data from the ongoing pediatric clinical trial and results from a clinical immunology study, which support the safety and efficacy of RUCONEST® [Recombinant Human C1 Esterase Inhibitor/conestat alfa]. The ongoing pediatric study is an open label Phase II clinical trial assessing safety, immunogenicity and efficacy in children 2-13 years of age with C1INH deficiency. Eight children were treated on demand for 28 HAE attacks at 50 IU/kg body weight (up to a maximum of 4200 IU). Efficacy endpoints were time to onset of relief and to minimal symptoms, assessed by the patient (assisted by their parent), using a visual analogue scale (VAS) and by physicians using an Investigator Score. Median time to beginning of relief was 60 minutes as determined by the patients and the investigators. Using the VAS, 93% of patients had onset of relief within 2 hours. No related serious adverse events, including hypersensitivity reactions, were reported. The second study investigated the immunogenicity of host (rabbit) related impurities (<0.002%) in 26 subjects with allergies to cow's milk and/or rabbit dander. Subjects were challenged with increasing doses of rhC1INH by skin prick, followed by intra-cutaneous injections, and finally sub-cutaneous challenge. No subjects (with pre-existing rabbit allergy or cow's milk allergy) had any confirmed clinical and laboratory evidence of hypersensitivity to rhC1INH.

Pharming Group NV and Cytobioteck S.A.S. Announce Distribution Agreement for Ruconest

Pharming Group NV announced that it has entered into an exclusive distribution agreement with Cytobioteck S.A.S. for the distribution of RUCONEST(R) (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in Colombia and Venezuela. Under the agreement, Cytobioteck will drive all regulatory processes and will purchase its commercial supplies of RUCONEST from Pharming at a fixed transfer price.

Pharming Group NV Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Pharming Group NV announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced that revenues increased to EUR 1.8 million compared to EUR 1.4 million for the same period a year ago, mainly as a result of product sales in the US. As a result of the increase in gross profit which equaled the increase of operating costs, the operating loss of EUR 3.0 million was in line with the first quarter of the previous year. The net loss decreased by EUR 14.7 million to EUR 1.3 million in the first quarter of 2015 compared to EUR 16.0 million for the same period a year ago. The net loss per share for the first quarter of 2015 decreased to EUR 0.003 compared to EUR 0.044 for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHARM:NA €0.28 EUR -0.004

PHARM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.96 EUR -0.36
BioCryst Pharmaceuticals Inc $15.32 USD +0.18
Oxford Biomedica PLC 9.14 GBp +0.19
Shire PLC 5,190 GBp -40.00
View Industry Companies

Industry Analysis


Industry Average

Valuation PHARM Industry Range
Price/Earnings 13.5x
Price/Sales 6.0x
Price/Book 4.1x
Price/Cash Flow 13.3x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMING GROUP NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at